raltegravir + valproic acid

Raltegravir is an antiretroviral agent classified as an HIV integrase inhibitor. It works by inhibiting the HIV integrase enzyme, thereby preventing the integration of viral DNA into the host genome and blocking viral replication. Raltegravir is primarily used in combination with other antiretrovirals for the treatment of HIV infection[1][3]. Valproic acid is a broad-spectrum anticonvulsant and mood stabilizer used to control various types of seizures and to treat bipolar disorder. Its mechanisms include inhibition of voltage-gated sodium channels, modulation of T-type calcium channels, enhancement of GABAergic activity through increased GABA levels and receptor binding, inhibition of histone deacetylases (HDAC), and effects on multiple intracellular signaling pathways[4][6]. The combination "raltegravir + valproic acid" refers to co-administration rather than a fixed-dose product; there are no significant pharmacokinetic or clinically meaningful interactions between these two drugs when used together[5][8].

Other names

sodium valproate